Cancer
Malignant Lung Neoplasm
CI-CAN-00001140Explore in graph →
Top-level2,650 active trials51 approved drugs619 evidence items
- NCIt
- C7377
- ICD-10
- C33-C34
- DOID
- 1324
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001140Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,491)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07830095 | 5G-Enabled Remote Robotic-Assisted Bronchoscopy-Guided Cryoablation for Pulmonary Malignancies | not yet recruiting | N/A | 15 | Shanghai Chest HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831863 | A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior Chemoimmunotherapy | not yet recruiting | Phase 3 | 600 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT01720186 | Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer(SPI COHERENCE) | terminated | N/A | 46 | Institut Claudius RegaudOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03391869 | Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 339 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT03410043 | Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study | active not recruiting | Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04291755 | Development and Analysis of a Stool Bank for Cancer Patients | enrolling by invitation | — | 100 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04638751 | ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | suspended | — | 5,000 | Persephone BiosciencesINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04665856 | Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer(SKYSCRAPER-02C) | completed | Phase 3 | 123 | Hoffmann-La RocheINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05017025 | Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 32 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05267626 | Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | recruiting | Phase 1 / Phase 2 | 159 | Aulos Bioscience, Inc.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT05801133 | Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors | completed | Phase 2 | 41 | Hubei Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05863052 | Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population | active not recruiting | — | 72 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05952778 | Reminder Messages for Lung Cancer Screening | active not recruiting | — | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06077760 | A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)(INTerpath-002) | active not recruiting | Phase 3 | 868 | Merck Sharp & Dohme LLCINDUSTRY | 33 | Sep 18, 2026 | clinicaltrials |
| NCT06616623 | Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer | suspended | Phase 1 | 24 | Dwight OwenOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06692738 | A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 3 | 1,160 | AstraZenecaINDUSTRY | 26 | Sep 18, 2026 | clinicaltrials |
| NCT06767514 | Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1(HARMONi-7) | recruiting | Phase 3 | 780 | Summit TherapeuticsINDUSTRY | 17 | Sep 18, 2026 | clinicaltrials |
| NCT06863623 | The Effect of Immersive Virtual Reality and Relaxing Videos on Lung Cancer Patients | completed | N/A | 315 | Hacettepe UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07147361 | Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma(PB-PD1R-SCC) | active not recruiting | — | 800 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07435038 | Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 120 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07617337 | AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer | recruiting | Phase 1 | 102 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 18, 2026 | clinicaltrials |
| NCT07676383 | Precision Navigation to Improve Community Cancer Screening Participation | recruiting | N/A | 1,500 | Hunan Cancer HospitalOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07705334 | A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors(Luca-1) | recruiting | Phase 1 | 30 | SHY TherapeuticsINDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827183 | AI-Personalized Discharge Education for Patients After Lung Cancer Surgery(AI-LUNG) | recruiting | N/A | 156 | Xiamen UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827261 | A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 36 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07827885 | 20-Fr Versus 24-Fr Chest Drains After Uniportal VATS Lobectomy for NSCLC(DRAIN2024) | completed | N/A | 80 | Fondazione Policlinico Universitario Campus Bio-MedicoOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07828938 | Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing Intraoperative Assessment of Pulmonary Resection Quality for Lung Cancer(QualitySurg) | not yet recruiting | N/A | 2,400 | Fondation Hôpital Saint-JosephOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02393625 | Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 57 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 17, 2026 | clinicaltrials |
| NCT02704832 | Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)(PREPARE) | completed | N/A | 792 | Institut BergoniéOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04105270 | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial | recruiting | Phase 2 | 82 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04152499 | Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)(MK-2870-001) | active not recruiting | Phase 1 / Phase 2 | 1,410 | Klus Pharma Inc.INDUSTRY | 6 | Sep 17, 2026 | clinicaltrials |
| NCT04342429 | Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer | recruiting | N/A | 30 | Emory UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04544748 | A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies | completed | Phase 1 | 48 | AO GENERIUMINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT04738487 | Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003) | terminated | Phase 3 | 1,264 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Sep 17, 2026 | clinicaltrials |
| NCT05937074 | Metabolic Response to Food in Lung Cancer(METRIC) | terminated | — | 5 | Pennington Biomedical Research CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06287775 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06546839 | SPSIPB vs SAPB for Thoracoscopic Surgery | completed | N/A | 46 | Medipol UniversityOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07084610 | Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | Hospital das Clínicas de Ribeirão PretoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07195695 | Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations | recruiting | Phase 3 | 400 | Boehringer IngelheimINDUSTRY | 28 | Sep 17, 2026 | clinicaltrials |
| NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | recruiting | Phase 1 | 574 | Revolution Medicines, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.(TeLuRide-008) | recruiting | Phase 2 / Phase 3 | 750 | Eikon TherapeuticsINDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07459634 | A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC | recruiting | Phase 2 | 50 | Jazz PharmaceuticalsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07490860 | A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to Increase Lung Cancer Screening Among Black Community Members, RESTORE Trial | recruiting | N/A | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | recruiting | Phase 3 | 356 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 17, 2026 | clinicaltrials |
| NCT07567352 | A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | active not recruiting | — | 200 | PfizerINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials